Abstracts

670 – Dolutegravir With Either Doravirine or Rilpivirine: Two-Drug Antiretroviral Therapy Outcomes

Background Dual nucleos(t)ide reverse transcriptase inhibitor (NRTI)-free regimens are an attractive choice for simplification of antiretroviral therapy (ART) in treatment-experienced patients. Fixed-dose formulation of rilpivirine (RPV) plus dolutegravir (DTG) is recommended for ART optimization, while Doravirine (DOR) plus DTG is a more recent NRTI-free option. We aimed to compare virologic suppression (VS) in treatment-experienced persons…

660 – Switch of Virally Suppressed Adults ≥ 60 Years From First-Line ART to B/F/TAF: Week 96 Results

Background Antiretroviral options for older adults are limited by age-related co-morbidities and drug toxicities. We evaluated whether a first line switch strategy in older adults maintains viral suppression while minimizing contribution to comorbidities. Methods The bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)-elderly study was an open-label, randomized, non-inferiority trial conducted at two sites in Kenya. HIV-1 positive adults ≥60…

681 – Low-Level Viremia and Risk Factors for Failure on Long-Acting Cabotegravir/Rilpivirine (LA CAB/RPV)

Background LA CAB/RPV has transformed the HIV treatment paradigm as an alternative to daily oral antiretroviral therapy (ART). Potential challenges with CAB/RPV include therapeutic failures characterized by virologic failure and/or the development of resistance-associated mutations (RAMs). Methods This was a single-center, retrospective cohort study of adults with HIV on LA CAB/RPV at the Ohio State…

696 – Predictive Factors of Virologic Failure After Switching to B/F/TAF (ANRS-CO3-AquiVIH-NA)

Background Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) is a simple highly potent antiretroviral (ART) regimen with a high genetic barrier to resistance. However, real-world evidence in the presence of drug resistance mutations (DRMs) remains limited. We investigated virological factors associated to virological failure (VF) after switching to B/F/TAF in individuals with pre-existing DRMs. Methods We performed a retrospective…

715 – Machine Learning Identifies Predictors of Delayed Remdesivir Use in Hospitalized COVID-19 Patients

Background COVID-19 remains a public health concern despite availability of effective interventions. Clinical studies have shown that remdesivir (RDV) reduces mortality, hospitalization, disease progression, and recovery time in individuals hospitalized with COVID-19. Current NIH guidelines recommend RDV treatment for patients at high risk of disease progression. This study of patients hospitalized for COVID-19 aimed to…

666 – ALLIANCE OLE: Switch to B/F/TAF in People With Both HIV-1 and HBV

Background In treatment-naïve adults with HIV-1 and hepatitis B virus (HBV) co-infection, the ALLIANCE study showed that bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was noninferior for HIV-1 RNA suppression and superior for HBV DNA suppression compared to dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) at Week [W] 48. Suppression rates were maintained through W96, after which DTG+F/TDF participants switched to…

705 – Creating an Ultralong-Acting Dolutegravir Prodrug Homodimer

Background Dolutegravir (DTG) is a widely used effective integrase strand transfer inhibitor with a high barrier to resistance. It is a recommended first-line treatment regimen for HIV-1-infected adults and children. However, DTG’s impact is limited by its daily dose requirements and suboptimal adherence. Long-acting formulations would improve optimal usage and reduce the emergence of drug…

688 – First Year of Lenacapavir Long-Acting Injectable Use in the OPERA Cohort

Background Lenacapavir (LEN), a first in class capsid inhibitor approved by the FDA (22DEC2022) as a twice yearly long-acting injectable used with an optimized background regimen (OBR), is indicated for heavily treatment-experienced individuals with multidrug resistant HIV-1 infection who are failing their current antiretroviral therapy (ART) regimen due to resistance, intolerance, or safety concerns. We…

694 – Forgiveness of Dolutegravir-Based Regimens Using Medication Possession Ratio: Andhra Pradesh, India

Background Adherence to antiretroviral therapy (ART) is independently associated with viral load (VL) suppression among people living with HIV (PLHIV). Previous studies have demonstrated that dolutegravir-based regimens (DBR) have forgiveness for strict adherence to achieve VL suppression (VLS) as measured by pharmacy refill and electronic drug monitoring, where 75% and 80% adherence, respectively, can achieve…

668 – Impact of Switching From DTG/3TC to BIC/FTC/TAF on Weight, Cholesterol, and Inflammation in HIV

Background DTG/3TC and BIC/FTC/TAF are recommended ART regimens in major HIV guidelines. However, data on the metabolic and inflammatory effects of switching from DTG/3TC to BIC/FTC/TAF are scarce. We investigated the impact of this switch on metabolic parameters and systemic inflammation in virologically suppressed individuals.  Methods This randomized, open-label, multicenter INSTINCT study (GESIDA10918) assessed the…